May 11, 2022

Visus Therapeutics, Inc., and Zhaoke Ophthalmology Limited Announce Exclusive Licensing Agreement to Commercialize BRIMOCHOL™ PF and Carbachol PF in Greater China, South Korea and Select Southeast Asian Markets for the Treatment of Presbyopia

NEWS: Visus Therapeutics Initiates Phase 3 Pivotal Trials of BRIMOCHOL™ PF for the Treatment of Presbyopia
LEARN MORE >
CLICK TO CLOSE
Click to Open

illuminating
OUR MISSION

Visus Therapeutics™ is a clinical-stage pharmaceutical company lighting the way to dramatically improve patient lives through the development of differentiated, best-in-class ophthalmic therapies.

And we're just getting started...

DISCOVER OUR PIPELINE TODAY
Discover our pipeline today.

With officies in Seattle and Orange County, Visus is home to our lead clinical candidate, BRIMOCHOL™ (carbachol + brimonidine tartrate), an eye drop being evaluated to correct the loss of near vision associated with presbyopia.

illuminating
OUR MISSION

Visus Therapeutics™ is a clinical-stage pharmaceutical company lighting the way to dramatically improve patient lives through the development of differentiated, best-in-class ophthalmic therapies.

And we're just getting started...

DISCOVER OUR PIPELINE TODAY
Discover our pipeline today.

With officies in Seattle and Orange County, Visus is home to our lead clinical candidate, BRIMOCHOL™ (carbachol + brimonidine tartrate), an eye drop being evaluated to correct the loss of near vision associated with presbyopia.

Visus Therapeutics announce spositive Phase 2 Topline results for Investigational Brimichol [& Brimochol F] for the treatment of presbropia

LEARN MORE